CardiArc Announces Independent Research Program for New SPECT Imaging System
Posted on: Wednesday, 30 May 2007, 15:00 CDT
LUBBOCK, Texas, May 30 /PRNewswire/ -- CardiArc, Inc. today announced it has established a research and testing program in which healthcare research institutions will be loaned CardiArc(R) SPECT system devices. The company is seeking independent testing, evaluations in clinical settings and publication of results regarding the design and performance of its cardiovascular camera.
Cleveland Clinic will receive the first commercially manufactured unit, which is expected to be installed in July. Other agreements are in the works and will be announced soon.
"We're very proud one of the world's premier healthcare institutions, es- pecially noted for its excellence in cardiovascular and nuclear medicine, has agreed to serve as our first clinical evaluation site for our production model," noted Jack Juni, M.D., F.A.C.N. P., CardiArc's founder and chief tech- nology officer. "Clinical testing and research will be invaluable in ensuring the CardiArc SPECT system meets the highest possible standards in cardiac di- agnostic imaging and patient care."
Evaluation will consist of at least 100 scans performed on individuals us- ing both the CardiArc SPECT system and again on a clinical SPECT machine cur- rently in use at Cleveland Clinic. All patient identification information will be removed. Additionally, a database will be created of CardiArc scans of nor- mal hearts at rest and under stress, and also scans of diseased hearts. Manuel Cerqueira, M.D., the Clinic's chairman of the department of nuclear medicine and past president of the American Society of Nuclear Cardiology will serve as principal investigator.
The CardiArc SPECT system provides faster imaging times and the industry's highest resolution - all in less floor space than any other SPECT system - with less than one minute setup time, radiation shielding for the technologist and superb patient comfort. It is currently available for purchase and will be displayed (booth #509) June 2 - 5 at the Society of Nuclear Medicine's 54th annual meeting in Washington, D.C.
The CardiArc SPECT device has been specifically optimized for use in out- patient settings and emergency rooms. It can pass through a standard 36-inch wide doorway, can be used in a 6- by 7-foot exam room, requires no room modi- fications for installation or operation and uses U.S. or European standard voltage. Power consumption is less than 200 watts.
SPECT is a standard noninvasive diagnostic imaging procedure performed and widely available in most hospitals and some outpatient clinics. It creates very accurate, three-dimensional images of blood flow and function of a major organ, such as the heart or brain. Energy from a radionuclide (tracer) which has been injected into the body is detected by a scanner, which takes a number of images from different angles, similar to the way a CAT scan produces im- ages. SPECT is highly accurate in detecting coronary artery disease.
About CardiArc, Inc.
CardiArc, Inc. (http://www.cardiarc.com/) is a medical device company founded in 2000 by internationally recognized nuclear physician and designer Jack Juni, MD, FACNP, to develop and bring to market superior SPECT imaging systems. The company has more than 30 patents issued or pending. Its highly accomplished management team includes Don Stull, PE, MBA, CEO; David M. Joseph, MD, presi- dent & chief medical officer, Terry Garner, vice president sales & marketing and a world-class medical advisory board. CardiArc, with offices in Texas and Michigan, is growing a highly experienced national sales team.
CardiArc, Inc.
CONTACT: Bill Wolfson of Landau Public Relations, +1-614-851-6748,bwolfson@LandauPR.com, for CardiArc, Inc.; or Terry Garner, VP Sales &Marketing of CardiArc, Inc., +1-262-242-4378, tgarner@CardiArc.com
Web site: http:/// http://www.cardiarc.com/
Source: PRNewswire
Related Articles
- Because of Its Ability to Generate Higher Total Sales in the United States and Europe, Lucentis Will Earn Clinical Gold Standard Status By 2011 for the Treatment of Diabetic Retinopathy
- InTouch Health Partners With Neurostar to Add Clinical Image Management Services to Telestroke Offering
- EarlySense Receives FDA Clearance for Its Contact-Free Patient's Clinical Status Monitor
- MEDecision's Patient Clinical Summary To Be Implemented By Memphis Managed Care Corporation
- Neurochem's New Agent Will Become the Clinical Gold Standard for the Treatment of Alzheimer's Disease in 2008
- St. Alexius Medical Center Installs World's First Symbia S SPECT System; Siemens Molecular Imaging Technology Enables Earlier Diagnosis
- Study at Emory Shows Varian Medical Systems' On-Board Imager(TM) Device Improves Tumor Targeting Without Slowing Clinical Workflow
- GE Healthcare Introduces Discovery VCT, the World's First Volumetric PET/CT System; Breakthrough Molecular Imaging Technology Capitalizes on Innovation of GE's LightSpeed VCT and Discovery PET/CT Systems
- The Present Role of Nuclear Cardiology in Clinical Practice
- The Role of Labeled Annexin A5 in Imaging of Programmed Cell Death: From Animal to Clinical Imaging
 |
 |
User Comments (0)
RSS Feeds